"These results suggest racial differences in the relationship between cytokine SNPs and risk of lung cancer, but larger studies need to be conducted in diverse populations to confirm these findings," said Dr. Schwartz.
According to Van Dyke, this type of information might be used to better predict who to screen for lung cancer for earlier disease detection and may lead to more targeted treatments.
"It is important that we identify disease markers for lung cancer," she said. "If diagnosed at a localized stage, the overall five-year survival rate is approximately 50 percent, yet when lung cancer is diagnosed a distant stage of disease, the five-year survival rate is only two percent."
Dr. Schwartz added, "Lung cancer remains the number one cancer killer among men and women in the United States. "If we can better predict who is at risk and then diagnose disease earlier, rates of survival will improve dramatically."
The study was funded by the National Cancer Institute. Other Karmanos Cancer Institute and Wayne State University investigators include Michele L. Cote, Ph. D., assistant professor of Internal Medicine; Angie S. Wenzlaff, M.P.H., research assistant, Epidemiology; Susan Land, Ph. D., principal investigator, Genomics Core; and Geoffry Prysak, M.P.H. and Gina B. Claeys, M.P.H., project managers.
About the Barbara Ann Karmanos Cancer Institute
Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer
Institute is one of 39 National Cancer Institute-designated comprehensive
cancer centers in the United States. Caring for more than 6,000 new
patients annually on a budget of $216 million, conducting more than 700
cancer-specific scientific investigation programs and clinical trials, the
Karmanos Cancer Institute is among th
|SOURCE Karmanos Cancer Institute|
Copyright©2008 PR Newswire.
All rights reserved